Genovate Biotechnology Co (ROCO:4130) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Genovate Biotechnology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Genovate Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Genovate Biotechnology Co's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.00). It may suggest that Genovate Biotechnology Co is progressively becoming more dependent on debt to grow their business.

Genovate Biotechnology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Genovate Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovate Biotechnology Co LT-Debt-to-Total-Asset Chart

Genovate Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Genovate Biotechnology Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Genovate Biotechnology Co LT-Debt-to-Total-Asset Calculation

Genovate Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.018	/	1600.456
	=	0.00

Genovate Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	1.962	/	1617.225
	=	0.00

Genovate Biotechnology Co (ROCO:4130) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Genovate Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Genovate Biotechnology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovate Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036

Website

http://www.genovate-bio.com

Genovate Biotechnology Co Ltd develops, produces, manufactures, and markets pharmaceutical preparations, drug substances, and intermediates. The company is also engaged in sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc.

Genovate Biotechnology Co Headlines

No Headlines